Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.4K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.4K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

438
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
438
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

331
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
331
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

307
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
307
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

328
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
328
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

68
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
68

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Edaravone provides neuroprotection against chronic heat stress-induced behavioral dysfunction through adaptive proteomic remodeling.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

The effects of chemotherapy on brain regions: implications for chemobrain revealed through metabolomic profiling.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Emerging biomarkers for early detection of colorectal cancer.

Clinica chimica acta; international journal of clinical chemistry·2026
Same author

HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Intranasal co-delivery of riluzole and berberine via chitosan-coated PLGA nanoparticles for synergistic neuroprotection in Alzheimer's disease: formulation, characterization, and pharmacokinetics analysis.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Treatment-Specific Prediction Models in Multiple Myeloma: A Critical Review of Current Evidence and Future Directions.

European journal of haematology·2026

Related Experiment Video

Updated: Mar 16, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.8K

An introduction to physiologically-based pharmacokinetic models.

Richard N Upton1, David J R Foster2, Ahmad Y Abuhelwa2

  • 1Australian Centre for Pharmacometrics and Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia. richard.upton@unisa.edu.au.

Paediatric Anaesthesia
|August 24, 2016
PubMed
Summary

Physiologically-based pharmacokinetic (PBPK) models simulate drug behavior in the body using organ-specific data. These models enable accurate scaling of drug kinetics across different body sizes and species.

Keywords:
anesthesiacomputer simulationpediatricspharmacokineticsphysiologyregional blood flow

More Related Videos

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

2.0K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.6K

Related Experiment Videos

Last Updated: Mar 16, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.8K
Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

2.0K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.6K

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Systems Biology
  • Computational Biology

Background:

  • Physiologically-based pharmacokinetic (PBPK) models integrate physiological and anatomical data to simulate drug disposition.
  • These models differ from traditional compartmental models by representing 'real' organs and processes.
  • PBPK models can be constructed using a 'bottom-up' approach, utilizing first principles and in vitro data.

Purpose of the Study:

  • To describe the fundamental principles and construction of PBPK models.
  • To illustrate the linking of organ submodels into a whole-body PBPK model.
  • To highlight the utility of PBPK models for scaling drug kinetics across different populations and species.

Main Methods:

  • Detailed explanation of PBPK model principles, including equations for flow-limited and membrane-limited compartments.
  • Description of how individual organ models are integrated to form a whole-body model.
  • Discussion of parameterization strategies, including 'bottom-up' versus 'top-down' approaches.

Main Results:

  • PBPK models provide a mechanistic representation of drug kinetics, focusing on measurable physiological processes.
  • The models are particularly advantageous for extrapolating pharmacokinetic data across different body sizes (e.g., neonates) and species (e.g., animal to human).
  • Availability of commercial software and generic solvers enhances the accessibility of PBPK modeling.

Conclusions:

  • PBPK models offer a robust framework for understanding and predicting drug kinetics.
  • Their ability to incorporate physiological variability makes them valuable for drug development and personalized medicine.
  • The primary challenge in PBPK modeling lies in the rigorous collection, collation, and justification of data for parameterization.